RayKnowChina Research Map
Shortlist

RecruitingBreast cancerN/A

Registered title, quoted from ClinicalTrials.gov

Electroacupuncture Treatment of Peripheral Neuropathy After Taxane Chemotherapy for Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Affiliated Hospital of Qinghai University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorAffiliated Hospital of Qinghai University青海大学附属医院XiningHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06772935, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to 75 years; sex: women only

    Registered eligibility fields

  2. Breast cancer patients diagnosed by pathology;

    Inclusion criterion 1

    Accept regular follow-up visits; ⑨ There is complete pathological data available.

    Inclusion criterion 4

  3. Received electroacupuncture treatment within 6 months prior to the start of the study;

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06772935, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Breast cancer patients diagnosed by pathology;
  • EOOG score is 0 or 1;
  • The age range for enrollment is between 18 and 75 years old; ④ Accept chemotherapy regimens based on taxane drugs (alone or in combination);

⑤ Previously received taxane chemotherapy for more than 6 months;

⑥ According to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) 5.0, reporting CIPN symptoms of grade 1 or higher for more than 2 weeks;

⑦ Voluntarily participate in this clinical trial and sign the informed consent form;

  • Accept regular follow-up visits; ⑨ There is complete pathological data available.

Exclusion Criteria:

  • Non breast cancer patients;
  • Received electroacupuncture treatment within 6 months prior to the start of the study;
  • Patients who experience intolerable toxic side effects during standard dose chemotherapy and terminate the chemotherapy cycle;
  • Prior to enrollment, there was a history of peripheral neuropathy;
  • Unstable heart disease or myocardial infarction within the first 6 months of the study;

⑥ Active skin diseases or surface skin ulcers or infections that cannot tolerate electroacupuncture treatment;

⑦ Uncontrolled epilepsy patients with uncontrolled seizures;

⑧ Merge with other malignant tumor patients;

⑨ Pregnancy and lactation period;

⑩ Refusal to join clinical trial patients

Quoted from ClinicalTrials.gov, NCT06772935, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06772935, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06772935